Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis

Marie Robin, Federica Giannotti, Eric Deconinck, Mohamad Mohty, Mauricette Michallet, Guillermo Sanz, Patrice Chevallier, Jean Yves Cahn, Faezeh Legrand, Montserrat Rovira, Jakob Passweg, Jorge Sierra, Stephanie Nguyen, Natacha Maillard, Ibrahim Yakoub-Agha, Werner Linkesch, Paul Cannell, Magda Marcatti, Jacques Olivier Bay, Yves ChalandonNicolaus Kröger, Eliane Gluckman, Vanderson Rocha, Eduardo Olavarria, Annalisa Ruggeri

Research output: Contribution to journalArticle

Abstract

To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P= .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.

Original languageEnglish
Pages (from-to)1841-1846
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Primary Myelofibrosis
Fetal Blood
Transplantation
Acute Myeloid Leukemia
Disease-Free Survival
Neutrophils
Whole-Body Irradiation
Cyclophosphamide
Blood Platelets
Survival Rate
Transplants
Survival
Incidence
Population

Keywords

  • Myelofibrosis
  • Umbilical cord blood transplantation

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Cite this

Robin, M., Giannotti, F., Deconinck, E., Mohty, M., Michallet, M., Sanz, G., ... Ruggeri, A. (2014). Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. Biology of Blood and Marrow Transplantation, 20(11), 1841-1846. https://doi.org/10.1016/j.bbmt.2014.06.011

Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. / Robin, Marie; Giannotti, Federica; Deconinck, Eric; Mohty, Mohamad; Michallet, Mauricette; Sanz, Guillermo; Chevallier, Patrice; Cahn, Jean Yves; Legrand, Faezeh; Rovira, Montserrat; Passweg, Jakob; Sierra, Jorge; Nguyen, Stephanie; Maillard, Natacha; Yakoub-Agha, Ibrahim; Linkesch, Werner; Cannell, Paul; Marcatti, Magda; Bay, Jacques Olivier; Chalandon, Yves; Kröger, Nicolaus; Gluckman, Eliane; Rocha, Vanderson; Olavarria, Eduardo; Ruggeri, Annalisa.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 11, 01.11.2014, p. 1841-1846.

Research output: Contribution to journalArticle

Robin, M, Giannotti, F, Deconinck, E, Mohty, M, Michallet, M, Sanz, G, Chevallier, P, Cahn, JY, Legrand, F, Rovira, M, Passweg, J, Sierra, J, Nguyen, S, Maillard, N, Yakoub-Agha, I, Linkesch, W, Cannell, P, Marcatti, M, Bay, JO, Chalandon, Y, Kröger, N, Gluckman, E, Rocha, V, Olavarria, E & Ruggeri, A 2014, 'Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis', Biology of Blood and Marrow Transplantation, vol. 20, no. 11, pp. 1841-1846. https://doi.org/10.1016/j.bbmt.2014.06.011
Robin, Marie ; Giannotti, Federica ; Deconinck, Eric ; Mohty, Mohamad ; Michallet, Mauricette ; Sanz, Guillermo ; Chevallier, Patrice ; Cahn, Jean Yves ; Legrand, Faezeh ; Rovira, Montserrat ; Passweg, Jakob ; Sierra, Jorge ; Nguyen, Stephanie ; Maillard, Natacha ; Yakoub-Agha, Ibrahim ; Linkesch, Werner ; Cannell, Paul ; Marcatti, Magda ; Bay, Jacques Olivier ; Chalandon, Yves ; Kröger, Nicolaus ; Gluckman, Eliane ; Rocha, Vanderson ; Olavarria, Eduardo ; Ruggeri, Annalisa. / Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 11. pp. 1841-1846.
@article{6e0d5a7ab8e9477f84f05dc650bf04f7,
title = "Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis",
abstract = "To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80{\%}. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44{\%} and 30{\%}, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44{\%} versus 0{\%}, P= .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.",
keywords = "Myelofibrosis, Umbilical cord blood transplantation",
author = "Marie Robin and Federica Giannotti and Eric Deconinck and Mohamad Mohty and Mauricette Michallet and Guillermo Sanz and Patrice Chevallier and Cahn, {Jean Yves} and Faezeh Legrand and Montserrat Rovira and Jakob Passweg and Jorge Sierra and Stephanie Nguyen and Natacha Maillard and Ibrahim Yakoub-Agha and Werner Linkesch and Paul Cannell and Magda Marcatti and Bay, {Jacques Olivier} and Yves Chalandon and Nicolaus Kr{\"o}ger and Eliane Gluckman and Vanderson Rocha and Eduardo Olavarria and Annalisa Ruggeri",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.bbmt.2014.06.011",
language = "English",
volume = "20",
pages = "1841--1846",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis

AU - Robin, Marie

AU - Giannotti, Federica

AU - Deconinck, Eric

AU - Mohty, Mohamad

AU - Michallet, Mauricette

AU - Sanz, Guillermo

AU - Chevallier, Patrice

AU - Cahn, Jean Yves

AU - Legrand, Faezeh

AU - Rovira, Montserrat

AU - Passweg, Jakob

AU - Sierra, Jorge

AU - Nguyen, Stephanie

AU - Maillard, Natacha

AU - Yakoub-Agha, Ibrahim

AU - Linkesch, Werner

AU - Cannell, Paul

AU - Marcatti, Magda

AU - Bay, Jacques Olivier

AU - Chalandon, Yves

AU - Kröger, Nicolaus

AU - Gluckman, Eliane

AU - Rocha, Vanderson

AU - Olavarria, Eduardo

AU - Ruggeri, Annalisa

PY - 2014/11/1

Y1 - 2014/11/1

N2 - To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P= .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.

AB - To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P= .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.

KW - Myelofibrosis

KW - Umbilical cord blood transplantation

UR - http://www.scopus.com/inward/record.url?scp=84908069791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908069791&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.06.011

DO - 10.1016/j.bbmt.2014.06.011

M3 - Article

C2 - 24946719

AN - SCOPUS:84908069791

VL - 20

SP - 1841

EP - 1846

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -